The development of an oral GLP-1 pill, aleniglipron, marks a significant advancement in the treatment of obesity and overweight. This small molecule can be taken once daily, with or without food, making it a more accessible option for those seeking to manage their weight.
Key Insights
Aleniglipron has demonstrated its efficacy in clinical trials, where it helped adults with obesity or overweight achieve weight loss of up to 12.1% of their body weight in 36 weeks. The treatment was well-tolerated, with mild to moderate gastrointestinal side effects being the primary concern. As a small-molecule GLP-1 drug that can be taken orally, aleniglipron presents a potentially simpler and more convenient alternative to traditional injectable obesity medications.
